Planview Unveils New Visual Identity at 2019 Global SAFe Summit
2.10.2019 16:05:00 EEST | Business Wire | Press release
Today, at the 2019 Global SAFe Summit in San Diego, California, Planview unveiled a bold new corporate visual identity. Since 1989, Planview has been on the forefront of providing award-winning enterprise solutions for managing work and resources. Now, Planview enters this next chapter as the premier platform for enabling every organization to seamlessly transform strategy to delivery in today’s changing world of work.
“Planview has been on a remarkable transformational journey with industry-leading growth and capability expansion, and it is an exciting day with the launch of our new corporate identity,” said Planview CEO Greg Gilmore. “Over the past year we have rewired Planview – today we are a bold, agile enterprise solutions leader that delivers breadth and scale for addressing all the ways organizations and teams work. The new Planview logo and visual design truly embody who we have become and where we are heading with our customers.”
The company’s new logo mark is inspired by forward-looking transformational leaders who – like peregrine falcons – require speed, agility, and keen vision to change altitude and swoop quickly in response to business and market changes and to help every team deliver value aligned to organizational strategy. The shades of red in the falcon symbolize the heroic journey these leaders and organizations must traverse in pursuit of bold advancements.
On October 2 and 3 at the Global SAFe Summit, attendees can experience how Planview solutions enable them to realize Agile at scale and make the project to product shift in the changing world of work. Planview will also demonstrate its new Agile costing solution, which eliminates manual time reporting and reduces the financial challenges of Agile at scale. By breaking down silos, connecting teams, integrating portfolios, and providing executive level visibility enterprise-wide, Planview solutions ensure organizations can plan and scale more effectively to deliver customer value faster.
Next week, Planview is hosting Planview Horizons – its 22nd annual customer conference – October 8-10 at the JW Marriott in Austin, Texas. “We really look forward to celebrating this new chapter in the company’s history with our customers and partners at Planview Horizons 2019. They are at the center of everything we do, and it is an honor to be by their sides for every one of their transformational journeys,” affirmed Gilmore.
About Planview
There is a bold new way of working, where every individual and team can move seamlessly from strategy to successful delivery – every day. Planview makes it possible. We empower you with a single line of sight across your entire organization and help every team collaborate to create value. Imagine realizing Agile at scale, creating a culture of innovation, and making the product shift. You are a change agent. So are we. For more information, visit www.planview.com.
Planview® and Planview Horizons® are registered trademarks of Planview, Inc.
All other trademarks listed herein are owned by their respective companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191002005203/en/
Contact information
Planview, Inc.
Karoline McLaughlin
kmclaughlin@planview.com
+1 512 596 3493
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom